CPRX Catalyst Pharmaceuticals Inc

Price (delayed)

$13.79

Market cap

$1.47B

P/E Ratio

23.37

Dividend/share

N/A

EPS

$0.59

Enterprise value

$1.35B

Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), anti-MuSK ...

Highlights
Catalyst Pharmaceuticals's gross profit has surged by 87% YoY and by 16% QoQ
The revenue has soared by 82% YoY and by 15% QoQ
Catalyst Pharmaceuticals's equity has increased by 29% YoY but it has decreased by 7% QoQ
Catalyst Pharmaceuticals's quick ratio has shrunk by 51% YoY and by 31% QoQ
The stock's P/E is 47% more than its 5-year quarterly average of 15.9 and 28% more than its last 4 quarters average of 18.2

Key stats

What are the main financial stats of CPRX
Market
Shares outstanding
106.61M
Market cap
$1.47B
Enterprise value
$1.35B
Valuations
Price to book (P/B)
4.22
Price to sales (P/S)
4.22
EV/EBIT
16.74
EV/EBITDA
12.83
EV/Sales
3.88
Earnings
Revenue
$348.39M
EBIT
$80.81M
EBITDA
$105.42M
Free cash flow
$127.89M
Per share
EPS
$0.59
Free cash flow per share
$1.2
Book value per share
$3.27
Revenue per share
$3.27
TBVPS
$2.31
Balance sheet
Total assets
$413.21M
Total liabilities
$64.66M
Debt
$3.28M
Equity
$348.55M
Working capital
$134.21M
Liquidity
Debt to equity
0.01
Current ratio
3.32
Quick ratio
2.92
Net debt/EBITDA
-1.12
Margins
EBITDA margin
30.3%
Gross margin
86.4%
Net margin
17.8%
Operating margin
21.8%
Efficiency
Return on assets
15.1%
Return on equity
18.3%
Return on invested capital
262%
Return on capital employed
22.7%
Return on sales
23.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CPRX stock price

How has the Catalyst Pharmaceuticals stock price performed over time
Intraday
-1.5%
1 week
4.63%
1 month
-5.29%
1 year
-11.15%
YTD
-17.97%
QTD
-17.97%

Financial performance

How have Catalyst Pharmaceuticals's revenue and profit performed over time
Revenue
$348.39M
Gross profit
$301.04M
Operating income
$75.92M
Net income
$62.04M
Gross margin
86.4%
Net margin
17.8%
Catalyst Pharmaceuticals's gross profit has surged by 87% YoY and by 16% QoQ
The revenue has soared by 82% YoY and by 15% QoQ
Catalyst Pharmaceuticals's net margin has shrunk by 53% QoQ and by 49% YoY
The operating margin has shrunk by 52% QoQ and by 50% YoY

Growth

What is Catalyst Pharmaceuticals's growth rate over time

Valuation

What is Catalyst Pharmaceuticals stock price valuation
P/E
23.37
P/B
4.22
P/S
4.22
EV/EBIT
16.74
EV/EBITDA
12.83
EV/Sales
3.88
The stock's P/E is 47% more than its 5-year quarterly average of 15.9 and 28% more than its last 4 quarters average of 18.2
The EPS has declined by 46% since the previous quarter and by 9% year-on-year
Catalyst Pharmaceuticals's equity has increased by 29% YoY but it has decreased by 7% QoQ
The stock's price to book (P/B) is 12% less than its last 4 quarters average of 4.8 and 4.1% less than its 5-year quarterly average of 4.4
The revenue has soared by 82% YoY and by 15% QoQ
The price to sales (P/S) is 40% lower than the 5-year quarterly average of 7.0 and 30% lower than the last 4 quarters average of 6.0

Efficiency

How efficient is Catalyst Pharmaceuticals business performance
The ROIC has dropped by 75% since the previous quarter but it is up by 3.2% year-on-year
The ROS has dropped by 51% since the previous quarter and by 47% year-on-year
CPRX's return on assets is down by 49% since the previous quarter and by 39% year-on-year
The ROE has decreased by 49% from the previous quarter and by 36% YoY

Dividends

What is CPRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CPRX.

Financial health

How did Catalyst Pharmaceuticals financials performed over time
Catalyst Pharmaceuticals's quick ratio has shrunk by 51% YoY and by 31% QoQ
CPRX's current ratio is down by 46% year-on-year and by 28% since the previous quarter
Catalyst Pharmaceuticals's debt is 99% lower than its equity
Catalyst Pharmaceuticals's equity has increased by 29% YoY but it has decreased by 7% QoQ
Catalyst Pharmaceuticals's debt has decreased by 10% YoY and by 2.8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.